Christian Grøndahl Steps Down As CEO Of Kymab Chairman David Chiswell Takes Over As Interim CEO

Cambridge, UK, 9 February 2015: Kymab, a leader in the discovery and development of human therapeutic monoclonal antibodies generated using its unique discovery platform, today announces that, due to his family commitments, Dr Christian Grøndahl will be stepping down as Chief Executive Officer of Kymab with immediate effect. Dr David Chiswell, Kymab's Chairman, takes over as interim CEO until a new, permanent CEO is appointed.

Dr David Chiswell, Chairman and interim CEO of Kymab said: "On behalf of the Board of Directors, I would like to thank Christian for his significant contribution to Kymab. Under his leadership, the company has successfully raised $40m in a second funding round from two of the world's largest foundations, the Wellcome Trust and The Bill and Melinda Gates Foundation, providing a strong foundation on which Kymab can enter its next stage of growth. We wish him every success in his next venture. We look forward to continuing the implementation of Kymab's strategy in building a substantial global biopharmaceutical company."


About Kymab

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse antibody platform.

Kymouse has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse partnership agreement was concluded with Novo Nordisk in 2013.

Founded in 2009, Kymab has raised over $70m of equity financing from the Wellcome Trust and the Bill & Melinda Gates Foundation. It has an experienced management team with a successful track record in drug discovery and development and has 12 current therapeutic antibody discovery programmes in immune-oncology, auto-immunity, haematology, chronic pain, dyslipidaemia and cardiovascular diseases. Kymab, Kymouse, Kymab Access are trademarks of Kymab Limited.

For further information contact:

Hume Brophy
Mary Clark
Tel: +44 (0)20 3440 5653, Email: [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.